ACME LaboratoriesDHA:ACMELAB +0.24%82 Pretax Margin % is 8.34% as of Mar. 2026, which is 25% below its 10-year median of 11.09. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT125.08 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, ACME Laboratories ranks better than 54.72% on this metric.
The historical rank and industry rank for ACME Laboratories's Pretax Margin % or its related term are showing as below:
DHA:ACMELAB'
s Pretax Margin % Range Over the Past 10 Years
Min: 8.84 Med: 11.09 Max: 14.99
Current: 8.84
DHA:ACMELAB's Pretax Margin % is ranked better than 54.72% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs DHA:ACMELAB: 8.84
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
ACME Laboratories Pretax Margin % Related Terms
ACME Laboratories Pretax Margin % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Pretax Margin % of 8.34% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ACME Laboratories and its competitors. This is 25% below median its historical median of 11.09. Over the past decade, ACME Laboratories' Pretax Margin % has ranged from 8.84 to 14.99. According to the industry distribution chart, ACME Laboratories ranks #432 out of 954 companies in the Drug Manufacturers industry, placing it in the top 45.3%.
Is ACME Laboratories' Pretax Margin % too high?
ACME Laboratories' current Pretax Margin % of 8.34% is 25% below median its 10-year median of 11.09. Over the past 10 years, this metric has ranged from a low of 8.84 to a high of 14.99. The Drug Manufacturers industry median Pretax Margin % is 7.30. ACME Laboratories' value of 8.34% is 14.3% above this industry median. Based on the distribution chart, ACME Laboratories ranks #432 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #432 out of 954 companies for Pretax Margin %. This puts ACME Laboratories in the upper half of its industry. The industry median Pretax Margin % is 7.30. ACME Laboratories' value of 8.34% is 14.3% above this benchmark. Historically, ACME Laboratories' own Pretax Margin % has ranged from 8.84 to 14.99 over the past decade. While the company's 10-year median is 11.09 vs. the industry median of 7.30, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Pretax Margin % of 8.34% is 14.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Pretax Margin % is 8.34%, which is 25% below median its own 10-year median of 11.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.08, compared to a current price of BDT82.60 — trading 34% below its estimated fair value. The current Pretax Margin % is 8.34%, which is 25% below median its 10-year median of 11.09 and 14.3% above the Drug Manufacturers industry median of 7.30. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Pretax Margin % is 8.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.60 is trading 34% below its estimated GF Value™ of BDT125.08.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Pretax Margin %: 8.34% (25% below median its 10-year median of 11.09)
GF Value™: BDT125.08 vs. price of BDT82.60 (34% below fair value)
Industry Position: 14.3% above the Drug Manufacturers median (#432 of 954)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
